Unichem Laboratories Ltd

- No explicit mention of new fundraising through debt or equity in the provided transcript. - The company discussed capital expenditures of Rs. 125-150 Crores for the current year and a similar amount next year, primarily funded through internal accruals and cash flow. - There is mention of treasury funds from the sale of SEZ invested in AAA-rated companies; these funds may be withdrawn for future capex or dividends. - No indication of plans to raise fresh funds via debt or equity in the near term; focus is on managing growth using internal resources. - Any future capex related to biosciences might impact spending but no clear fundraising strategy stated.

- Capital expenditure for the current year has crossed Rs. 100 Crores, primarily on Goa expansion, Pithampur API expansion, and a new site at Kolhapur, Maharashtra. - Total capex for the current year expected between Rs. 125 to Rs. 150 Crores. - Next year (FY 2017) expects a similar capex level, around Rs. 100 Crores, largely for the second phase of Goa expansion and Kolhapur API plant. - The Kolhapur plant is being developed as a world-class facility capable of passing US FDA and other international inspections. - The plant will be commissioned in phases over about two years, helping free capacity in existing US FDA approved plants. - Possible additional capex on biosciences if opportunities arise. - Internal accruals and treasury funds from SEZ sale are used for investment, with fixed deposits in AAA-rated companies for liquidity.

- The domestic formulation business showed strong 19%-20% growth in Q3 FY16, expected to continue robust double-digit growth in FY2017 and FY2018. - Chronic business, including legendary brands like Losar and Trika, are gaining positive market traction and expected to sustain growth. - New product launches planned for Q4 and FY2017, including for the Gliptin segment, are anticipated to add to volume and value growth. - International formulations, especially in the US market, showed 16% growth; similar or higher growth is targeted in FY2017 with new product approvals and launches. - Capex around Rs. 125-150 Cr spent in the current year, with a similar amount expected for expansion in FY2017, supporting growth. - Employee productivity improvements and business restructuring efforts are expected to support sustainable growth. - The US subsidiary has shown 39% turnover growth with profits, indicating positive outlook for international business growth.

- Q4 and upcoming quarters are expected to continue good growth momentum, building on strategic decisions and improved productivity (Page 5). - FY2017 is expected to show robust double-digit growth in domestic formulations and overall business (Page 5). - International formulations, especially US market, are targeted to maintain or exceed current growth levels (~16% growth) with new product launches; overall international business double-digit growth anticipated (Pages 8, 10). - Employee cost impact from bonus act exceptional items is expected to normalize in Q4 and going forward (Pages 5-6). - Capex plans (~Rs. 100 Crores next year) aimed at expanding capacity and supporting growth (Page 6). - New product launches in US and domestic markets expected to contribute to earnings growth (Pages 4, 9). - The US subsidiary and international business profitable growth continues, with US subsidiary showing 39% turnover growth and profits of $0.8 million for 9 months (Page 2).

The document does not explicitly mention the current or expected order book or pending orders for Unichem Laboratories Limited as of January 2016. However, relevant insights include: - The company has around 15 pending ANDA (Abbreviated New Drug Application) filings in the US market. - Out of those, 14 products have already been launched. - Several approvals are awaited, with some filings expected every quarter. - The company is focused on cost-competitive products with established market demand. - There is no specific numerical data shared on order book size or expected pending order revenue. - Management declined to comment on market size or addressable opportunity for pending approvals. Thus, while product pipeline filings and regulatory approvals are progressing, explicit order book or pending order values are not disclosed in the provided content.